Barbara Buldini
Overview
Explore the profile of Barbara Buldini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reiterova M, Kohlscheen S, Maglia O, Sala S, Schumich A, Maurer-Granofszky M, et al.
Clin Chem Lab Med
. 2025 Mar;
PMID: 40068909
Objectives: Risk-based stratification approaches using measurable residual disease (MRD) successfully help to identify T-acute lymphoblastic leukemia (T-ALL) patients at risk of relapse, whose treatment outcomes are very poor. Because of...
2.
Mastrodicasa E, Pagliaro L, Pierini V, Bardelli V, Giaimo M, Zamponi R, et al.
Haematologica
. 2025 Feb;
PMID: 40013393
Not available.
3.
Buldini B, Varotto E
Haematologica
. 2024 Jun;
109(10):3088-3090.
PMID: 38934058
No abstract available.
4.
Kimura S, Park C, Montefiori L, Iacobucci I, Polonen P, Gao Q, et al.
Cancer Discov
. 2024 Jun;
14(10):1838-1859.
PMID: 38916500
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand...
5.
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia
van Weelderen R, Harrison C, Klein K, Jiang Y, Abrahamsson J, Alonzo T, et al.
Blood Adv
. 2024 Apr;
8(12):3200-3213.
PMID: 38621200
A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study on 1256 children...
6.
Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Bruggemann M, et al.
Blood
. 2024 Jan;
143(17):1738-1751.
PMID: 38215390
In the effort to improve immunophenotyping and minimal residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL), the international Berlin-Frankfurt-Münster (iBFM) Flow Network introduced the myelomonocytic marker CD371 for a...
7.
Conter V, Valsecchi M, Cario G, Zimmermann M, Attarbaschi A, Stary J, et al.
J Clin Oncol
. 2023 Dec;
42(8):915-926.
PMID: 38096462
Purpose: The AIEOP-BFM ALL 2009 protocol included, at the end of the induction phase, a randomized study of patients with high-risk (HR) ALL to investigate if an intensive exposure to...
8.
Tretti Parenzan C, Molin A, Longo G, Gaffo E, Buratin A, Cani A, et al.
Blood Adv
. 2023 Nov;
8(5):1305-1319.
PMID: 38029383
Circular RNAs (circRNAs) are emerging molecular players in leukemogenesis and promising therapeutic targets. In KMT2A::AFF1 (MLL::AF4)-rearranged leukemia, an aggressive disease compared with other pediatric B-cell precursor (BCP) acute lymphoblastic leukemia...
9.
Kimura S, Polonen P, Montefiori L, Park C, Iacobucci I, Yeoh A, et al.
medRxiv
. 2023 Nov;
PMID: 37986997
Purpose: Gamma delta T-cell receptor-positive acute lymphoblastic leukemia (γδ T-ALL) is a high-risk but poorly characterized disease. Methods: We studied clinical features of 200 pediatric γδ T-ALL, and compared the...
10.
Buldini B, Faggin G, Porcu E, Scarparo P, Polato K, Tregnago C, et al.
Cytometry A
. 2023 Oct;
103(12):1004-1009.
PMID: 37876342
In the development of novel immunotherapeutic approaches, the step of target identification is a challenging process, because it aims at identifying robust tumor-associated antigens (TAAs) specific for the pathological population...